Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. / Musto, Pellegrino; Santini, Valeria; Balestri, Francesca; Fabbri, Alberto; Falcone, Antonietta; Sanpaolo, Grazia.

In: Haematologica, Vol. 87, No. 3, 2002, p. 322-3.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Musto, P, Santini, V, Balestri, F, Fabbri, A, Falcone, A & Sanpaolo, G 2002, 'Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.', Haematologica, vol. 87, no. 3, pp. 322-3.

APA

Musto, P., Santini, V., Balestri, F., Fabbri, A., Falcone, A., & Sanpaolo, G. (2002). Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica, 87(3), 322-3.

Vancouver

Musto P, Santini V, Balestri F, Fabbri A, Falcone A, Sanpaolo G. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica. 2002;87(3):322-3.

Author

Musto, Pellegrino ; Santini, Valeria ; Balestri, Francesca ; Fabbri, Alberto ; Falcone, Antonietta ; Sanpaolo, Grazia. / Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. In: Haematologica. 2002 ; Vol. 87, No. 3. pp. 322-3.

Bibtex

@article{8d4b1d20acae11ddb5e9000ea68e967b,
title = "Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.",
abstract = "Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L.Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.",
author = "Pellegrino Musto and Valeria Santini and Francesca Balestri and Alberto Fabbri and Antonietta Falcone and Grazia Sanpaolo",
note = "Keywords: Aged; Aged, 80 and over; Amifostine; Drug Evaluation; Drug Therapy, Combination; Erythropoietin, Recombinant; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome",
year = "2002",
language = "English",
volume = "87",
pages = "322--3",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "3",

}

RIS

TY - JOUR

T1 - Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.

AU - Musto, Pellegrino

AU - Santini, Valeria

AU - Balestri, Francesca

AU - Fabbri, Alberto

AU - Falcone, Antonietta

AU - Sanpaolo, Grazia

N1 - Keywords: Aged; Aged, 80 and over; Amifostine; Drug Evaluation; Drug Therapy, Combination; Erythropoietin, Recombinant; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome

PY - 2002

Y1 - 2002

N2 - Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L.Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

AB - Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L.Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

M3 - Journal article

C2 - 11869946

VL - 87

SP - 322

EP - 323

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -

ID: 8463466